BioSpace News Archive

Atamyo Therapeutics announced the first authorization of a Clinical Trial Application in Europe for ATA-200, its gene therapy for the treatment of the γ-sarcoglycan related limb-girdle muscular dystrophy Type 2C/R5.

Osivax announced that all participants have completed their final visit in the Phase 2a clinical trial evaluating OVX836, Osivax’ broad-spectrum influenza A vaccine candidate, in combination with Quadrivalent Influenza Vaccines.

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance, provided an update on its Phase 2a proof of concept study evaluating PRAX-628 in epilepsy patients with PPR.

Veeda Clinical Research Limited, a full-service contract research organization with a proven record of drug development success, announced that it has acquired Heads, a privately held European CRO, which specializes in conducting clinical trials in oncology.

FibroGen, Inc. announced that Thane Wettig, Chief Executive Officer, will participate in a corporate presentation at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, from 3:00-3:40 PM Eastern Time.

InspireMD, Inc. announced that an abstract of the one-year outcomes from its C-GUARDIANS IDE clinical trial of the CGuard™ Prime Carotid Stent System for the treatment of carotid artery stenosis has been accepted for presentation at the Leipzig Interventional Course 2024, which is being held May 28-31, in Leipzig, Germany.

Acumen Pharmaceuticals, Inc. reported financial results for the full year ended December 31, 2023 and provided a business update.

Bristol Myers Squibb unveiled a $1.8 million initiative to advance health equity by addressing social determinants of health in four countries with underserved patient needs, including Brazil, India, Thailand, and the United Kingdom.

Nanoscope Therapeutics Inc. announced positive top-line results after the completion of the 2-year Phase 2b RESTORE randomized, controlled clinical trial of its lead program, MCO-010, a mutation-agnostic gene therapy for patients with permanent and severe vision loss from advanced retinitis pigmentosa.

Protagonist Therapeutics, Inc. announced it has randomized 241 patients in the ongoing Phase 3 VERIFY clinical trial evaluating rusfertide in polycythemia vera as of and expects to meet the trial’s 250 patient enrollment target by the end of March 2024.